Composite Adverse Event Outcome in Pediatric Cancer Patients with Prolonged Febrile Neutropenia

Yıl 2016, , 69 - 73, 01.06.2016

Muhammad Matloob

https://doi.org/10.5799/jmid.vi.328804

Öz

Objective: Pediatric cancer patients with prolonged febrile neutropenia have increased risk for severe, recurrent or new
bacterial and fungal infection. The aim of this study was to identify the risk factors associated with adverse outcomes
in this group.
Methods: We retrospective analyzed the clinical data of 135 hospitalizations of pediatric cancer patients with prolonged
febrile neutropenia from a tertiary health care center of Pakistan.
Results: The mean age of the study population was 7.3±4.1 years. There were 98 (72.6%) males and 37 (27.4%) females.
Acute leukemia with 88 patients (65.2%) was the most common diagnosis followed by lymphomas 19 patients (14.1%)
and solid tumors. Cause of febrile neutropenia was identified in only 58 (43.0%) patients, out of them blood stream
infections were found in 22 cases (16.3%), pneumonia in 15 (11.1%), fungal infection in 13 (9.6%), infectious diarrheas
in 5 (3.7%) and urinary tract infection (UTI) in 3 (2.2%) of cases. The composite adverse event outcome was observed
in 28 (20.7%) of patients, with in-hospital mortality occurring in 7 (5.2%), Pediatric intensive care unit (PICU) admission
occurring in 12 (8.9%) and inotropic support was required in 9 (6.7%). On logistic regression analysis AML (Adjusted
odds ratio (AOR), 7.6; P<0.001), neutropenia <50/mm3
(AOR, 10.8; p<0.001), platelets count <50,000/mm3
(AOR, 5.2;
p<0.001), BSI (AOR, 2.3; p 0.05) and fungal infection (AOR, 4.3; p<0.001) were found as independent risk factors for
composite adverse event outcome in pediatric cancer patients with prolonged febrile neutropenia.
Conclusions: AML, severe myelosuppression, blood stream infections and fungal infection were identifiable risk factors
associated with development of adverse event outcome in pediatric cancer patients with prolonged febrile neutropenia.
J Microbiol Infect Dis 2016;6(2): 69-73   

Anahtar Kelimeler

Febrile neutropenia, pediatric, oncology, adverse outcome

Kaynakça

• 1. Ellis M. Febrile neutropenia evolving strategies. Ann NY Acad Sci 2008;1138:329-350.
• 2. Meckler G, Lindemulder S. Fever and neutropenia in pediatric patients with cancer. Emerg Med Clin North Am 2009;27:525- 544.
• 3. Walsh TJ RE, Groll AH, Gonzalez C, Pizzo P. Infectious complications in pediatric cancer patients. In: Pizzo PA, Poplack DG, eds. Principles & Practice of Pediatric Oncology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkens, 2005:1269- 1275.
• 4. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-1332.
• 5. Hughes WT, Armstrong D, Bodey GP, et al: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.
• 6. Ozer H, Armitage JO, Bennett CL, et al: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines-American Society of Clinical Oncology Growth and Factors Expert Panel. J Clin Oncol 2000;18:3558-3585.
• 7. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:427-431.
• 8. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control, 2008;36:309-332.
• 9. De Pauw B, Walsh TJ, Donnelly JP, et al. Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008 June 15;46:1813- 1821.
• 10. Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol, 2012;30:p.4427-4438.
• 11. Santolaya ME, Alvarez AM, Aviles CL, et al. Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenic episode. Pediatr Infect Dis J 2007;26:794-798.
• 12. Mendes AV, Sapolnik R, Mendonca N. New guidelines for the clinical management of febrile neutropenia and sepsis in pediatric oncology patients. J Pediatr (Rio J), 2007;83:S54-63.
• 13. Basu SK, Fernandez ID, Fisher SG, et al. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol 2005;23:7958-7966.
• 14. Phillips B, Selwood K, Lane SM, et al. Variation in policies for the management of febrile neutropenia in United Kingdom Children’s Cancer Study Group centres. Arch Dis Child 2007;92:495-498.
• 15. Santolaya ME, Alvarez AM, Aviles CL, et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clin Infect Dis 2002;35:678-683.
• 16. Klaassen RJ, Goodman TR, Pham B, Doyle JJ. “Low-risk” prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000;18:1012-1019.
• 17. Fletcher M, Hodgkiss H, Zhang S, et al. Prompt administration of antibiotics is associated with improved outcomes in febrile neutropenia in children with cancer. Pediatr Blood Cancer 2013;60:1299-306.
• 18. Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol 2001; 19: 3415-3421.
• 19. Rackoff WR, Gonin R, Robinson C, et al. Predicting the risk of bacteremia in childen with fever and neutropenia. J Clin Oncol 1996;14:919-924.
• 20. Lucas KG, Brown AE, Armstrong D, et al. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996; 77: 791-798.
• 21. Timothy M, Bodkyn C. The outcome of febrile neutropenic episodes in paediatric oncology at the Wendy Fitzwilliam Paediatric Hospital. West Indian Med J 2011; 60: 153-157.